Enis Aboalhasan

Enis Aboalhasan

Auto-generated profile, based on publicly available information

Enis Aboalhasan

Maximizing Health Outcomes Research Lab, Sapir College, Sderot, Israel

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
JAJoseph Azuri
Joseph Azuri
AHAriel Hammerman
Ariel Hammerman
EAEnis Aboalhasan
Enis Aboalhasan
BSBen Sluckis
Ben Sluckis
RARonen Arbel
Ronen Arbel
Aims: Higher doses of the glucagon‐like peptide‐1 agonist semaglutide and, more recently, tirzepatide, a dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 agonist showed a significant reduction in body weight in patients with type 2 diabetes mellitus. However, their comparative value for money for this indication is unclear. Therefore, we aimed to establish which provides better value for money. Materials and Methods: We calculated the cost needed to treat to achieve a 1% reduction in body weight using high‐dose tirzepatide (15 mg) versus semaglutide (2.4 mg). The body weight reductions were extracted from published results of SURMOUNT‐1 and STEP 1 trials, respectively. In addition, we performed a scenario analysis to mitigate the primary differences between the two study populations. Drug costs were based on US GoodRx prices as of October 2022. Results: Using tirzepatide resulted in a weight loss of 17.8% (95% CI: 16.3%‐19.3%) compared with 12.4% (95% CI: 11.5%‐13.4%) for semaglutide. The total cost of 72 weeks of tirzepatide was estimated at $17 527 compared with $22 878 for 68 weeks of semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with tirzepatide is estimated at $985 (95% CI: $908‐$1075) compared with $1845 (95% CI: $1707‐$1989) with semaglutide. Scenario analysis confirmed these findings. Conclusions: Tirzepatide provides better value for money than semaglutide for weight reduction.

19 May 2023 in Obesity
Verified
Journal Article
Open access
JAJoseph Azuri
Joseph Azuri
AHAriel Hammerman
Ariel Hammerman
EAEnis Aboalhasan
Enis Aboalhasan
BSBen Sluckis
Ben Sluckis
RARonen Arbel
Ronen Arbel
Objective: Higher doses of the glucagon‐like peptide‐1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.Methods: The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.Results: Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%‐5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%‐13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032‐$3517) compared with $1845 (95% CI: $1707‐$1989) with semaglutide.Conclusions: Semaglutide provides significantly better value for money than liraglutide for weight reduction.

17 December 2020 in European Journal of Preventive Cardiology
Verified
Journal Article
Closed access
RARonen Arbel
Ronen Arbel
EAEnis Aboalhasan
Enis Aboalhasan
AHAriel Hammerman
Ariel Hammerman
JAJoseph Azuri
Joseph Azuri
Aims: The Angiotensin Receptor-Neprilysin Inhibitor sacubitril-valsartan (ARNI) and dapagliflozin, a sodium-glucose transport protein 2 inhibitor, reduce the risk of heart failure hospitalization (hHF) and cardiovascular (CV) mortality in patients with reduced ejection fraction (HFrEF). Their comparative value for money is undetermined. Therefore, our aim was to compare the cost per outcome implications of utilizing dapagliflozin vs. ARNI for preventing heart failure (HF) events of non-diabetic patients with HFrEF. Methods and results: We calculated the cost needed to treat (CNT) to prevent one HF event. The cost needed to treat was estimated by multiplying the annualized number needed to treat (NNT) to prevent one event by each therapy’s annual cost. Efficacy estimates were extracted from published secondary analyses of non-diabetic patients in DAPA-HF and PARADIGM-HF trials. Drug costs were estimated as 75% of the 2020 US National Average Drug Acquisition Cost listing. Sensitivity analysis was performed to mitigate differences between the trial’s populations and drug costs in various countries. The annualized NNT to prevent one HF event for dapagliflozin was 31 (95% CI 21–71) vs. 33 (95% CI 24–62) for ARNI. The CNT of dapagliflozin in the US is $141 112 (95% CI $95 592–$323 192) compared to $158 169 (95% CI $115 032–$297 166) for sacubitril-valsartan. The CNT results were sensitive to drug costs in various countries. Conclusion: Dapagliflozin and ARNI provide comparable value for money for preventing HF events in non-diabetic patients with HFrEF. In healthcare settings where dapagliflozin’s price is significantly lower than ARNI, it provides superior value for money.


1 July 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
RARonen Arbel
Ronen Arbel
EAEnis Aboalhasan
Enis Aboalhasan
AHAriel Hammerman
Ariel Hammerman
JAJoseph Azuri
Joseph Azuri

20 February 2022 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AHAriel Hammerman
Ariel Hammerman
CMCandace Makeda Makeda Moore
Candace Makeda Makeda Moore
EAEnis Aboalhasan
Enis Aboalhasan
JAJoseph Azuri
Joseph Azuri
RARonen Arbel
Ronen Arbel